테고사이언스
Financials
Valuation Metrics
테고사이언스's Market Cap is ₩578B. At end of 2025 it was ₩1322B. Ranked #1609 of 2,410 in KR market (top 67%), #950 of 1,631 on KOSDAQ (top 58%), #178 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.82B KRW | KR#1,609/2,410 Sec#178/231 |
| Revenue | 6.18B KRW | KR#2,312/2,410 Sec#187/231 |
| Net Income | -12.92B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 76.38B KRW | KR#1,957/2,410 Sec#161/231 |
| Net Assets | 43.60B KRW | KR#1,993/2,410 Sec#173/231 |
| Employees | 39 | KR#2,129/2,410 Sec#197/231 |
| Value | ||
| P/B | 1.33x | KR#1,751/2,410 Sec#120/231 |
| P/S | 9.35x | KR#2,273/2,410 Sec#165/231 |
| FCF Yield | -5.39% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -29.64% | KR#2,171/2,410 Sec#172/231 |
| ROA | -16.92% | KR#2,205/2,410 Sec#170/231 |
| Op. Margin | -98.57% | KR#2,288/2,410 Sec#172/231 |
| Revenue Growth | -5.15% | KR#1,770/2,410 Sec#169/231 |
| Financial Health | ||
| Debt Ratio | 75.19% | KR#1,278/2,410 Sec#153/231 |
| Total Debt | 2.40B KRW | KR#1,879/2,410 Sec#184/231 |
| FCF | -3.12B KRW | KR#1,393/2,410 Sec#109/231 |
| Cash | 5.69B KRW | KR#1,961/2,410 Sec#179/231 |
| Current Ratio | 1.64x | KR#1,083/2,410 Sec#121/231 |
| Performance | ||
| 1Y Return | -59.83% | KR#2,150/2,410 Sec#199/231 |
| 1M Return | -0.42% | KR#362/2,410 Sec#37/231 |
| From 52W High | -62.07% | KR#1,736/2,410 Sec#144/231 |
| 1Y MDD | -69.57% | KR#1,935/2,410 Sec#162/231 |
| Trading | ||
| Volume | 654 shares | KR#2,319/2,410 Sec#229/231 |
| Trading Value | 4.7M KRW | KR#2,287/2,410 Sec#225/231 |
| Foreign Own. | 1.61% | KR#1,781/2,410 Sec#174/231 |
| Per Share | ||
| EPS | -1,593 KRW | KR—/2,410 Sec—/231 |
| BPS | 5,376 KRW | KR#1,454/2,410 Sec#104/231 |
Company Info
Tegosciece, established in 2001 and listed on KOSDAQ in 2014, specializes in the development, manufacturing, and sale of cell therapy products. Utilizing world-class cell culture technology, the company is a leader, holding three of 16 approved cell therapy products (Holoderm, Caloderm, Rosmir). Initially developing wound healing cell therapy products for burns and foot ulcers, Tegosciece is now expanding into regenerative medicine new drug development for musculoskeletal diseases, including domestic and U.S. clinical trials for rotator cuff tear treatment. It is headquartered in Gangseo-gu, Seoul.